| 2008 | May | 250th VentrAssist enrolment |
| | | |
| | 36 active centres in ten countries worldwide |
| | | |
| April | John Ward, ex-Qantas MD, appointed Chairman of the Board |
| | | |
| | Feasibility Trial Bridge-to-Transplant (BTT) Trial results report 86% success to end-point |
| | | |
| March | FDA grants unconditional approval for Destination Therapy (DT) Clinical Trial |
| | | |
| | First two implants of VentrAssist LVAD in India |
| | | |
| February | 200th VentrAssist enrolment |
| | | |
| 2007 | December | Major Industry Milestone |
| | | |
| | CE Mark approval for new version of VentrAssist LVAD |
| | | |
| November | 10 active US centres |
| | | |
| October | 150th VentrAssist implant |
| | | |
| September | First US Destination Therapy Trial implant |
| | | |
| August | Market approval in Australia by the Therapeutic Goods Administration (TGA) |
| | | |
| May | Start of US BTT pivotal trial |
| | | |
| April | 100th VentrAssist implant |
| | | |
| | FDA approval to start US Bridge to Transplant trial |
| | | |
| January | Feasibility Study - 10 patient enrolment achieved |
| | | |
| | FDA agreement to extension of Feasibility Trial |
| | | |
| | FDA agrees to US Bridge to Transplant (BTT) Pivotal Trial protocol, unconditional approval granted |
| | | |
| | A$2.8 million Commercial Ready Grant from Australian Federal Government to fund further development of the VentrAssist |
| | | |
| 2006 | December | CE Mark approval to market in Europe |
| | | |
| | FDA grants conditional approval for Destination Therapy (DT) Clinical Trial protocol |
| | | |
| | US Feasibility Trial 10 patient recruitment target achieved |
| | | |
| | US Bridge-To-Transplant (BTT) Pivotal Trial protocol agreed with FDA |
| | | |
| October | First Case of Heart Recovery with VentrAssist Reported |
| | | |
| | Submission of CE Mark Trial results to EU regulatory body |
| | | |
| September | CE Mark Clinical Trial Bridge-to-Transplant (BTT) Trial results report 83% success to end-point |
| | | |
| | Successful launch of VentrAssist in Europe |
| | | |
| August | Federal Health Minister Commissions Global Manufacturing Facility |
| | | |
| April | Appointment of key staff in Europe in preparation for market launch |
| | | |
| March | Successful capital raising gives Ventracor $60 million cash |
| | | |
| February | CE Mark Trial recruitment complete |
| | | |
| | 50 human implants at trial sites around the world |
| | | |
| | First revenue of A$1.5 million |
| | | |
| 2005 | July | First US implant |
| | | |
| May | First implant in Europe |
| | | |
| February | US-based Peter Crosby appointed Chief Operating Officer |
| | | |
| 2004 | December | Investigational device exemption (IDE) lodged with US Food and Drug Administration (FDA) |
| | | |
| April | VentrAssist recognised for Excellence in Engineering and Design at the 2004 Australian Design Awards |
| | | |
| | New production facility and clean room commissioned |
| | | |
| February | Fifth Implant of the VentrAssist™ |
| | | |
| 2003 | November | Colin Sutton PhD appointed CEO |
| | | |
| October | Successful Rights Issue Lifts Cash Position to $74 million |
| | | |
| June | First Human Implant of the VentrAssist™ |
| | | |
| April | Ventracor joins S&P/ASX 200 index |
| | | |
| March | Final approval to begin human trials by The Alfred hospital Ethics Committee |
| | | |
| | Ventracor incorporated into the S&P/ASX 200 |
| | | |
| January | Sale of eHealth division |
| | | |
| 2002 | December | The Alfred hospital Ethics Committee indicates approval to begin human trials |
| | | |
| November | Submission to The Alfred hospital Ethics Committee to begin human trials for ‘artificial heart’ |
| | | |
| July | Shareholders ratify change of company name to Ventracor Limited |
| | | |
| May | Discussions commence with United States regulatory authority, the Food & Drug Administration (FDA), on the clinical trials process |
| | | |
| | Company has cash reserves in excess of $20 million to commence human implant trials of VentrAssist™ in Australia, Europe and the United States |
| | | |
| March | $A17.6 million placement of shares with international and national institutions, sophisticated investors and existing shareholders |
| | | |
| | Human placement trials for VentrAssist™ ‘artificial heart’ begin |
| | | |
| January | FDA clearance for sale of PocketView ECG, the first pocket-sized ECG based on a PDA. MicroMedical now has 13 FDA market cleared products |
| | | |
| | Mr Michael Spooner appointed Group Managing Director & CEO |
| | | |
| 2001 | November | VentrAssist™ project wins Business/Higher Education Round Table Award for outstanding achievement in collaborative research and development for 2001 |
| | | |
| September | PocketView and CardioView systems win Asia Pacific Information and Communications Technology Award |
| | | |
| August | VentrAssist™ achieves ISO 9001 Quality Assurance certification |
| | | |
| June | VentrAssist™ technology gains second US patent |
| | | |
| May | VentrAssist™ technology gains first US patent |
| | | |
| March | VentrAssist™ technology gains first Australian patent |
| | | |
| 2000 | November | CardioView ECG PC Link wins Queensland IT & T Award |
| | | |
| October | VentrAssist division receives AusIndustry award for Commitment to Innovation |
| | | |
